Diet and Meal Timing in Patients With Non-Alcoholic Fatty Liver Disease: A Pilot Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Percentage of Patients Who Achieve At Least 30% Reduction in Liver Fat at 12 Weeks
研究概览
简要总结
This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterranean diet and 30 minutes of exercise on at least 5 days/week) on the degree of fat in the liver as measured by magnetic resonance imaging.
详细描述
Time-Restricted Eating (TRE) is a form of caloric restriction through daily prolonged fasting that has been shown to lead to weight loss, improved glucose regulation, and suppression of inflammation. Non-alcoholic fatty liver disease (NAFLD) is a metabolic condition that in certain patients can lead to significant morbidity and mortality. The only current treatment for NAFLD is weight loss. In the proposed study, the investigators aim to test the hypothesis that TRE will add additional benefit in the treatment of NAFLD on top of standard of care diet and lifestyle modifications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age ≥ 18 and < 65 years old
- •Must provide signed written informed consent and agree to comply with the study protocol
- •BMI >25 kg/m²
- •Baseline liver fat content of at least 10% as measured by MRI-PDFF
排除标准
- •Unclear etiology of liver disease
- •Competing etiologies for hepatic steatosis
- •Co-existing causes of chronic liver disease according to standard diagnostic testing including, but not restricted to:
- •Positive hepatitis B surface antigen
- •Positive hepatitis C virus RNA
- •Suspicion of drug-induced liver disease
- •Alcoholic liver disease
- •Autoimmune hepatitis
- •Wilson's disease
- •Hemochromatosis
- •Primary biliary cholangitis or primary sclerosing cholangitis
- •Known or suspected hepatocellular carcinoma
- •Current or recent history (<5 years) of significant alcohol consumption. For men, significant consumption is defined as >30g of alcohol per day. For women, it is defined as >20g of alcohol per day.
- •Compensated and decompensated cirrhosis (clinical and/or histologic evidence of cirrhosis). NASH patients with fibrosis stage = 4 according to the NASH CRN fibrosis staging system are excluded.
- •Reduction in weight by ≥ 5% within the prior 90 days
- •Current fasting for ≥ 12 hours per day on the majority of days each week
- •Pregnant females
- •Mental instability or incompetence, such that the validity of the informed consent or ability to be compliant with the study is uncertain
- •Inability to perform MRI-PDFF and/or study as defined below
- •Inability to medically perform prolonged fasting (i.e. insulin regimen)
结局指标
主要结局
Percentage of Patients Who Achieve At Least 30% Reduction in Liver Fat at 12 Weeks
时间窗: 12 weeks
Evaluate the percentage of patients with baseline MASLD (MRI-PDFF greater than or equal to 10%) who achieve clinically significant improvement in hepatic fat, as defined by greater than or equal to 30% reduction from baseline liver fat on MRI-PDFF, while adopting a time-restricted eating pattern (fasting 16 hours per day) along with standard of care management as compared to patients with only standard of care NAFLD management.
次要结局
- Mean Change from Baseline in Quality of Life Score on SF-36 at 12 weeks(Baseline, 12 weeks)
- Mean Change from Baseline in BMI at 12 weeks(Baseline, 12 weeks)
- Mean Change from Baseline in Body Composition Measurements at 12 weeks(Baseline, 12 weeks)
- Mean Change from Baseline in aspartate transglutaminase at 12 weeks(Baseline, 12 weeks)
- Mean Change from Baseline in alanine transglutaminase at 12 weeks(Baseline, 12 weeks)
- Mean Change from Baseline in Weight at 12 weeks(Baseline, 12 weeks)
- Mean Change from Baseline in Liver Stiffness on Fibroscan® at 12 weeks(Baseline, 12 weeks)
- Mean Change from Baseline in total bilirubin at 12 weeks(Baseline, 12 weeks)
- Mean Change from Baseline in direct bilirubin at 12 weeks(Baseline, 12 weeks)
- Mean Change from Baseline in total protein at 12 weeks(Baseline, 12 weeks)
- Mean Change from Baseline in albumin at 12 weeks(Baseline, 12 weeks)